secwatch.observer — SEC 8-K summary
======================================

Issuer:     HCW Biologics Inc. (HCWB)
CIK:        0001828673
Form:       8-K
Filed at:   2025-11-18T23:59:59+00:00
Accession:  0001193125-25-285325
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HCW Biologics doses first patient in Phase 1 trial of HCW9302 for alopecia areata
--------------------------------------------------------------------------------

- First patient dosed at Ohio State University Wexner Medical Center in multi-center first-in-human Phase 1 trial.
- HCW9302 is a subcutaneous IL-2 fusion molecule designed to expand Treg cells, built on the TOBI platform.
- Trial plans to enroll up to 30 patients; primary objectives are safety and determination of recommended Phase 2 dose.
- Secondary endpoints include disease response and effects on Treg cell proliferation; expansion into other autoimmune and inflammatory conditions is planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828673/000119312525285325/0001193125-25-285325-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828673/000119312525285325/hcwb-20251117.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-285325

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer